Perrigo Co PLC (PRGO) Q2 2021 Earnings Call Transcript fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
Are These Top Health Care Stocks Worth Investing In Now? 4 To Consider
The health care industry has and continues to play a crucial role in our world today. Because of this, investors continue to turn towards the top health care stocks on the market. It is not surprising that most would be paying more attention to their overall health amidst these times. No doubt, as we are approaching the one-year mark for the current pandemic, health care remains crucial as ever.
The healthcare names we often hear about are the likes of vaccine superstars such as Moderna (NASDAQ: MRNA). Another newcomer in that department would be Johnson & Johnson (NYSE: JNJ) who just got U.S. FDA approval for its single-dose vaccine. Aside from that, innovations in the health care space are still plentiful outside of coronavirus-related research as well. Take AstraZeneca (NASDAQ: AZN) for example. Yes, it does have a vaccine candidate, but it recently sold its 7.7% stake in Moderna for almost $1 billion. From t
Perrigo sells generic drug business for $1.55 billion
Nick Manes, Crain s Detroit Business
Perrigo Company has sold its generic drug business.
The Allegan County, Pa.-based pharmaceutical company, which is domiciled for tax purposes in Ireland, announced Monday morning that it would offload the Generic Rx Pharmaceuticals business to New York-based private investment firm Altaris Capital Partners LLC for a total of $1.55 billion.
Perrigo said the deal includes $1.5 billion in cash and that Altaris will assume in excess of $50 million in potential milestone payments related to research and development, as well as contingent purchase obligations with third-party partners the company works with, according to a news release.
Share this article
Share this article
DUBLIN, March 1, 2021 /PRNewswire/ Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of
Consumer Self-Care Products, announced today that it has reached a definitive agreement to sell its Generic Rx Pharmaceuticals business to Altaris Capital Partners, LLC for total consideration of $1.55 billion, including $1.5 billion in cash, subject to customary adjustments. As part of the consideration, Altaris will also assume more than $50 million in potential R&D milestone payments and contingent purchase obligations with third-party Rx partners.
Perrigo CEO and President Murray S. Kessler commented, The sale of our Generic Rx business is the most impactful step in Perrigo s transformation plan. This transaction establishes Perrigo as a pure-play global consumer self-care company with industry leading fundamentals. Perrigo Consumer Self-Care will have a focused portfolio with over $4 billion in revenues focused on the growing tre
Perrigo to sell generic business to Altaris Capital Partners for $1 55 billion forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.